prescribing semaglutide for weight loss New Medication Wegovy™ Approved by the FDA Ozempic® & Wegovy® Weight-Loss Injections

12.1%) over 3.4 years [120]

[34] Knight JA

Postmenopausal women, in particular, experience a higher incidence of RA, which is often compounded by overweight and obesity, conditions that exacerbate disease severity 3

Strategic Role: As a high-volume cash cow with broad global reimbursement, it provides the stable cash flow necessary to fund Novos more aggressive R&D into next-generation combinations like CagriSema

Abstract Gastroesophageal reflux disease (GERD) is one of the common diseases of the digestive system, and its incidence is increasing year by year, in addition to its typical symptoms of acid reflux and heartburn affecting the quality of patients survival

Compounded GLP-1 medications are not FDA-approved finished products and outcomes are not guaranteed